Molecular Test Enhances Melanoma Diagnostic Accuracy
Diagnostic Test for Melanocytic Lesions
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
MIAdx is a molecular diagnostic assay designed to accurately distinguish melanoma from benign naevi using DNA sequencing of specific gene alterations. Developed by researchers at the University of Sydney and Melanoma Institute of Australia, the test offers over 95% specificity, addressing the limitations of subjective histopathology and reducing diagnostic errors. This tool provides objective assessments, aiding clinical decision-making and preventing over- or underdiagnosis. Applications include diagnostic labs and oncology centres, complementing histopathological analysis and integrating seamlessly into existing workflows. By improving diagnostic accuracy, MIAdx enhances patient outcomes and offers significant commercial potential for oncology-focused diagnostic companies.
IP Type or Form Factor: Patent Pending; Software & Algorithm; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Diagnostics & Screening; Healthcare Provider
